Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target

Author: Benzinga Newsdesk | March 28, 2024 10:34am
JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $12 price target.

Posted In: BCAB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist